http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
AlGaN-based deep ultraviolet light-emitting diodes on nanopatterned AlN/sapphire substrates
Donghyun LEE,Jong Won LEE,Jeonghwan JANG,In-Su SHIN,Lu JIN,Jungsub KIM,Jinsub LEE,Hye-Seok NOH,Yong-Il KIM,Youngsoo PARK,Gun-Do LEE,Yongjo PARK,Jong Kyu KIM,Euijoon YOON 한국진공학회 2016 한국진공학회 학술발표회초록집 Vol.2016 No.8
A Prospective Observation of Psychological Distress in Patients With Anaphylaxis
Youngsoo Lee,장형윤,Sang-Ha Kim,Min-Suk Yang,Young-Il Koh,Hye Ryun Kang,최정희,Cheol-Woo Kim,Hye Kyung Park,Joo Hee Kim,Young-Hee Nam,Tae-Bum Kim,Gyu-Young Hur,Jae-Woo Jung,Kyung-Hee Park,Mi-Ae Kim,김지웅,Jiwo 대한천식알레르기학회 2020 Allergy, Asthma & Immunology Research Vol.12 No.3
Purpose: Anaphylaxis is an immediate allergic reaction characterized by potentially life-threatening, severe, systemic manifestations. While studies have evaluated links between serious illness and posttraumatic stress disorder (PTSD), few have investigated PTSD after anaphylaxis in adults. We sought to investigate the psychosocial burden of recent anaphylaxis in Korean adults. Methods: A total of 203 (mean age of 44 years, 120 females) patients with anaphylaxis were recruited from 15 university hospitals in Korea. Questionnaires, including the Impact of Event Scale-Revised-Korean version (IES-R-K), the Korean version of the Beck Anxiety Inventory (K-BAI), and the Korean version of the Beck Depression Inventory (K-BDI), were administered. Demographic characteristics, causes and clinical features of anaphylaxis, and serum inflammatory markers, including tryptase, platelet-activating factor, interleukin-6, tumor necrosis factor-α, and C-reactive protein, were evaluated. Results: PTSD (IES-R-K ≥ 25) was noted in 84 (41.4%) patients with anaphylaxis. Of them, 56.0% had severe PTSD (IES-R-K ≥ 40). Additionally, 23.2% and 28.1% of the patients had anxiety (K-BAI ≥ 22) and depression (K-BDI ≥ 17), respectively. IES-R-K was significantly correlated with both K-BAI (r = 0.609, P < 0.0001) and K-BDI (r = 0.550, P < 0.0001). Among the inflammatory mediators, tryptase levels were lower in patients exhibiting PTSD; meanwhile, platelet-activating factor levels were lower in patients exhibiting anxiety and depression while recovering from anaphylaxis. In multivariate analysis, K-BAI and K-BDI were identified as major predictive variables of PTSD in patients with anaphylaxis. Conclusions: In patients with anaphylaxis, we found a remarkably high prevalence of PTSD and associated psychological distresses, including anxiety and depression. Physicians ought to be aware of the potential for psychological distress in anaphylactic patients and to consider psychological evaluation.
Lee, Jee-Hyun,Thanigaimalai, Pillaiyar,Lee, Ki-Cheul,Bang, Seong-Cheol,Kim, Min-Seok,Sharma, Vinay Kumar,Yun, Cheong-Yong,Roh, Eunmiri,Kim, Youngsoo,Jung, Sang-Hun The Pharmaceutical Society of Japan 2010 Chemical & pharmaceutical bulletin Vol.58 No.7
<P>In order to determine the optimum size of heterocycle of lead compound 1 (6-methyl-3-phenethyl-3,4-dihydro-1<I>H</I>-quinoline-2-thione; IC<SUB>50</SUB>=0.8 μ<SMALL>M</SMALL>) for inhibition of melanogenesis, we have synthesized and evaluated some benzimdazole-2(3<I>H</I>)-thiones 5a—e. The preliminary bioassay has shown that the benzimdazole-2(3<I>H</I>)-thione motif of 5 is essential structural unit for their inhibitory activity. Among all thiones 5a—e, the compound 5d strongly inhibited the formation of melanin with IC<SUB>50</SUB> value of 1.3 μ<SMALL>M</SMALL>.</P>
Lee, Youngsoo 한국산업정보응용수학회 1998 한국산업정보응용수학회 Vol.2 No.2
In this paper we define the entropy rate and stationary Markov chain and we show the monotonicity of entropy per element and prove that the random tree T_(n) grows linearly with n.
Lee, Hwa Dong,Lee, Won‐,Hee,Roh, Eunmiri,Seo, Chang‐,Seob,Son, Jong‐,Keun,Lee, Seung Ho,Hwang, Bang Yeon,Jung, Sang‐,Hun,Han, Sang‐,Bae,Kim, Youngsoo Blackwell Publishing Ltd 2011 Experimental dermatology Vol.20 No.9
<P><B>Abstract: </B> Microphthalmia‐associated transcription factor (MITF) is inducible in response to cAMP through the cAMP‐responsive element–binding protein (CREB) and plays a pivotal role in the melanocyte‐specific expression of tyrosinase or tyrosinase‐related proteins (TRPs) for melanin biosynthesis. Manassantin A from <I>Saururus chinensis</I> inhibits cAMP‐induced melanin production in B16 melanoma cells. Here, we focused on molecular basis of the antimelanogenic activity. Manassantin A consistently inhibited the cAMP elevator 3‐isobutyl‐1‐methylxanthine (IBMX)‐ or dibutyryl cAMP‐induced melanin production in B16 cells or in melan‐a melanocytes by down‐regulating the expression of <I>tyrosinase</I> or <I>TRP1</I> gene. Moreover, manassantin A suppressed MITF induction through IBMX‐activated CREB pathway, directly inhibiting the Ser‐133 phosphorylation of CREB. However, manassantin A did not affect IBMX‐increased cAMP levels in these cells but also other cAMP‐dependent melanogenic pathways through post‐translational modifications of MITF. This putative molecular mechanism of manassantin A in the inhibition of melanin production suggests its pharmacological potential in skin hyperpigmentation.</P>
KAAACI Guidelines for Allergen Immunotherapy
Lee Hwa Young,이상민,강성윤,Kim Kyunghoon,Kim Ju Hee,Ryu Gwanghui,Min Jin-Young,Park Kyung Hee,Park So-Young,Sung Myongsoon,Lee Youngsoo,Yang Eun Ae,Jee Hye Mi,Ha Eun Kyo,Shin Yoo Seob,Chung Eun Hee,Choi Su 대한천식알레르기학회 2023 Allergy, Asthma & Immunology Research Vol.15 No.6
Allergen immunotherapy (AIT) is a causative treatment for various allergic diseases such as allergic rhinitis, allergic asthma, and bee venom allergy that induces tolerance to offending allergens. The need for uniform practice guidelines in AIT is continuously growing because of the increasing discovery of potential candidates for AIT and evolving interest in new therapeutic approaches. This guideline is an updated version of the Korean Academy of Asthma Allergy and Clinical Immunology recommendations for AIT published in 2010. This updated guideline proposes an expert opinion by allergy, pediatrics, and otorhinolaryngology specialists with an extensive literature review. The guideline deals with basic knowledge and methodological aspects of AIT, including mechanisms, clinical efficacy, patient selection, allergens extract selection, schedule and doses, management of adverse reactions, efficacy measurements, and special consideration in pediatrics. The guidelines for sublingual immunotherapy will be covered in detail in a separate article.
Pot1a Prevents Telomere Dysfunction and ATM-Dependent Neuronal Loss
Lee, Youngsoo,Brown, Eric J.,Chang, Sandy,McKinnon, Peter J. Society for Neuroscience 2014 The Journal of neuroscience Vol.34 No.23
<P>Genome stability is essential for neural development and the prevention of neurological disease. Here we determined how DNA damage signaling from dysfunctional telomeres affects neurogenesis. We found that telomere uncapping by Pot1a inactivation resulted in an Atm-dependent loss of cerebellar interneurons and granule neuron precursors in the mouse nervous system. The activation of Atm by Pot1a loss occurred in an Atr-dependent manner, revealing an Atr to Atm signaling axis in the nervous system after telomere dysfunction. In contrast to telomere lesions, Brca2 inactivation in neural progenitors also led to ablation of cerebellar interneurons, but this did not require Atm. These data reveal that neural cell loss after DNA damage selectively engages Atm signaling, highlighting how specific DNA lesions can dictate neuropathology arising in human neurodegenerative syndromes.</P>
Clinical Application of Eritoran as Drug Candidate for Sepsis Treatment
Youngsoo Kim, Sun Hong Park, Kiho Lee, Hwa Kyung Lim, Sang-Bae Han 충북대학교 동물의학연구소 2011 Journal of Biomedical and Translational Research Vol.12 No.1
Sepsis is a clinical syndrome defined as a systemic inflammatory response to infection. Eritoran is a synthetic lipid A derivative that competes with lipopolysaccharide in binding to the identical site of myeloid differentiation-2/toll-like receptor 4 complex. Eritoran is effective in decreasing the septic mortality of Gram-negative bacteria-infected animals. Eritoran has been highlighted as a candidate drug for treatment of endotoxemia in phase I clinical studies with healthy human volunteers. A phase II trial of eritoran has been conducted in patients with severe sepsis. Intravenous infusion of eritoran reduced the mortality rate, as compared with the placebo group, in sepsis patients at a high risk of mortality according to acute physiology and chronic health evaluation-II scores. A phase III study of eritoran was completed in 2011. The results appear to be disappointing as no statistically significant difference in all-cause mortality was observed between the eritoran treatment group and the placebo group on day 28 in sepsis patients with a high risk of death. In this review, we focus on the rationale for the use of eritoran in treatment of sepsis as well as its clinical applications.